Icon

Veklury - (100 mg/vial ; Powder for Injection)

Remdesivir Gilead
100 mg/vial ; Powder for Injection
More Than $1000 mn
Less Than 5
Less Than 5
None None
None None
VEKLURY is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who are: • Hospitalized, or • Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
Yes
******* - *** **, ****
Veklury Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16
****** **** *** **** *** **** *** **** *** **** *** **** ** *** **, **** **** *** **** *** **** ** *** **, **** **** *** **** ** *** **, **** **** *** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* *** **, **** ******* **** *** ****** *** **** (**** ***)
  1. *** **, **** : * **** ** ** ***** *** ***** ** *** ***.
  2. *** **, **** : ****** (****** ******) ******** ****** ***** *** **** ** ******.
  3. *** **, **** : ****** **** ****** **** ************ ** ****** **. '***, '***, '***, '***, '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.